Generation Bio Co. reported a net loss of $14.8 million for Q1 2025, a substantial improvement from the $74.5 million net loss in Q1 2024. Collaboration revenue increased to $8.7 million, up from $4.1 million in the prior year, primarily due to a change in estimate related to research services. The company's operating expenses decreased significantly, mainly due to a lower loss on lease termination.

Generation Bio reported a net loss of $21.4 million for Q4 2024, with revenues of $4.188 million. The company's cash position remains strong at $185.2 million, expected to fund operations into the second half of 2027.

Generation Bio reported a net loss of $15.3 million for Q3 2024, an improvement compared to the $28.3 million net loss in Q3 2023. The company's cash, cash equivalents, and marketable securities totaled $199.8 million as of September 30, 2024, which is expected to fund operations into the second half of 2027.

Generation Bio reported a net loss of $20.4 million, or $0.31 per share, for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities were $216.9 million as of June 30, 2024, expected to fund operations into the second half of 2027.

Generation Bio reported a net loss of $74.5 million for Q1 2024. The company's cash, cash equivalents, and marketable securities totaled $233.9 million, expected to fund operations into the second half of 2027. The company presented new data on its ctLNP and iqDNA platforms.

Generation Bio is focusing on advancing its cell-targeted lipid nanoparticle and immune-quiet DNA platforms, with a focus on in vivo programs for sickle cell disease, beta-thalassemia, and hemophilia A. The company's cash balance is expected to fund operations into the second half of 2027.

Generation Bio reported a net loss of $28.3 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities were $291.0 million as of September 30, 2023, which is expected to fund operations into 2026. The company also highlighted advances in its iqDNA and ctLNP platforms.

Generation Bio reported a net loss of $31.1 million, or $0.47 per share, for the second quarter of 2023. The company's cash position remains strong at $314.1 million, expected to fund operations into 2025. They are focused on demonstrating Factor VIII expression in non-human primates for hemophilia A program.

Generation Bio reported a net loss of $32.1 million for the first quarter of 2023. The company's cash balance of $288.6 million is expected to fund operations into 2025. A strategic collaboration with Moderna was also announced.

Generation Bio reported a net loss of $32.4 million for the fourth quarter of 2022. The company's cash, cash equivalents, and marketable securities were $279.1 million as of December 31, 2022, which is expected to fund operations into 2025. The company is focusing on achieving proof-of-concept for its ctLNP delivery systems in 2023.

Generation Bio reported a net loss of $31.3 million for Q3 2022. The company's cash, cash equivalents, and marketable securities totaled $301.2 million, expected to fund operations into 2025. Phillip Samayoa, Ph.D. was named chief strategy officer.

Generation Bio reported a net loss of $37.9 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $312.2 million as of June 30, 2022, expected to fund operations into 2025.

Generation Bio reported a net loss of $35.0 million for the first quarter of 2022. The company's cash and cash equivalents were $337.0 million as of March 31, 2022, which is expected to fund operations into 2024. The company is focused on optimizing its ctLNP delivery system for liver, retina, and vaccine applications.

Generation Bio reported its Q4 and full-year 2021 financial results, highlighting a cash position of $375.1 million, which is expected to fund operations into 2024. The company is focused on advancing its genetic medicine platform across liver, retina, and vaccine applications.

Generation Bio reported a net loss of $31.9 million for Q3 2021, with cash, cash equivalents, and marketable securities totaling $398.4 million as of September 30, 2021. The company highlighted preclinical data demonstrating broad delivery of ceDNA and mRNA to photoreceptors using ctLNP.

Generation Bio reported a net loss of $30.8 million for the second quarter of 2021. The company is transitioning its portfolio to a next-generation rapid enzymatic manufacturing process and signed a lease to build a state-of-the-art cGMP facility.

Generation Bio reported a net loss of $25.6 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $451.1 million as of March 31, 2021. They also presented data demonstrating the broad potential of their gene therapy platform.

Generation Bio reported its Q4 and full year 2020 financial results, highlighting a strong cash position of $262.3 million at the end of 2020, bolstered by net proceeds from a follow-on offering, which funds key milestones into 2024. The company also remains on track to begin IND-enabling studies for hemophilia A in 2021.

Generation Bio reported a net loss of $20.8 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $280.4 million as of September 30, 2020. Key leadership appointments were also announced to support preclinical development programs.

Generation Bio reported a net loss of $17.7 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $301.1 million as of June 30, 2020, including $230.0 million from its IPO.